Vanda Pharmaceuticals (VNDA) Other Operating Expenses (2010 - 2026)

Vanda Pharmaceuticals has disclosed Other Operating Expenses across 17 years of filings, most recently posting $4.9 million for Q1 2026.

• Other Operating Expenses for Q1 2026 came in at $4.9 million, down 3.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $113.6 million (up 550.28% YoY), and the FY2025 annual result was $113.8 million, up 543.52% from the prior year.
• Other Operating Expenses came in at $4.9 million for Q1 2026 at Vanda Pharmaceuticals, down from $100.2 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $100.2 million in Q4 2025 to a low of $3.2 million in Q3 2023.
• The 5-year median for Other Operating Expenses is $4.9 million (2023), against an average of $10.4 million.
• Across the five-year window, Other Operating Expenses slumped 49.33% in 2023 and surged 2354.71% in 2025, its largest moves.
• Vanda Pharmaceuticals' Other Operating Expenses stood at $6.4 million in 2022, then sank by 33.73% to $4.2 million in 2023, then fell by 3.04% to $4.1 million in 2024, then soared by 2354.71% to $100.2 million in 2025, then tumbled by 95.13% to $4.9 million in 2026.
• The last three Other Operating Expenses figures came in at $4.9 million (Q1 2026), $100.2 million (Q4 2025), and $4.4 million (Q3 2025), per Business Quant data.